Venus Medtech (Hangzhou) Inc
02500
Company Profile
Business description
Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically majority of the revenue is derived from Mainland China.
Contact
No. 88, Jiangling Road
Room 311, 3rd Floor, Block 2
Binjiang District
Hangzhou310051
CHNT: +86 57187772180
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
605
Stocks News & Analysis
stocks
3 Warren Buffett stocks to avoid today
These are the most overvalued stocks in Berkshire Hathaway’s portfolio.
stocks
Should you invest in small caps?
With small capitalisation stocks gaining momentum, there are important considerations to determine whether they are right for your portfolio.
stocks
Strong second half anticipated for ASX mining play
A more focused business model should benefit the company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,079.20 | 17.70 | 0.20% |
| CAC 40 | 7,870.68 | 75.26 | 0.97% |
| DAX 40 | 23,739.47 | 204.64 | 0.87% |
| Dow JONES (US) | 46,247.29 | 299.97 | 0.65% |
| FTSE 100 | 9,284.83 | 70.85 | 0.77% |
| HKSE | 26,128.20 | 356.48 | -1.35% |
| NASDAQ | 22,484.07 | 99.37 | 0.44% |
| Nikkei 225 | 45,354.99 | 399.94 | -0.87% |
| NZX 50 Index | 13,111.73 | 42.06 | -0.32% |
| S&P 500 | 6,643.70 | 38.98 | 0.59% |
| S&P/ASX 200 | 8,787.70 | 13.20 | 0.15% |
| SSE Composite Index | 3,828.11 | 25.20 | -0.65% |